Figure 10 summarizes the protective effects of ethyl acetate fraction co-treatment against cardiac hypertrophy via MAPK and calcineurin-NFAT-GATA4 signaling pathway activation. The gene discussed is GATA4; the disease is cardiac hypertrophy.